European MDR approval for immunosuppressive or reactive treatment of patients who do not respond adequately to theracosis, corticosteroids and other drugs.

Summary

Dublin, 22 October 2026 — Global leader in the field of immunotherapy therapy through extracorporeal photopheresis (ECP) with patients, Therakos Development Limited has been certified by EU MDR for the adaptation extension of its therapeutic system THERAKOSTM CELLEXTM.